DOI: 10.36347/sajp.2023.v12i06.001

Pages: 121-126

Background: Numerous comorbidities, such as type 2 diabetes mellitus, hypertension, dyslipidemia, and cardiovascular (CV) disease are all made more likely by obesity. A higher mortality rate in the general population is strongly correlated with a high body mass index (BMI). In patients who are at high risk of experiencing an atherosclerotic CV event, the use of statins lowers mortality and recurrent adverse cardiac events across a broad range of cholesterol levels. Therefore, statin therapy is advised for secondary prevention in all high-risk patients, including those with obesity. Objectives: There is evidence to support the primary prevention of coronary artery disease, morbidity, and mortality using statins for lipid modifications. The purpose of this study is to ascertain the immediate impact of atorvastatin on the lipid profile in obese Jordanian patients. Methods: According to NCEP ATP III criteria, 200 overweight and obese patients with hypercholesterolemia were included. They received treatment for 2 months after being randomly divided into 3 groups based on the dosage of atorvastatin: 10, 20, and 40 mg/day. Results: With all atorvastatin doses, there was a significant desirable increase in high-density lipoprotein (HDL), and significant reduction in total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), and very low-density lipoprotein (VLDL). Conclusion: In dyslipidemic obese patients, short-term atorvastatin therapy resulted in lower levels of TC, TG, LDL, and VLDL as well as a desirable increase in HDL.